IDIQ for the purchase of human induced pluripotent stem cell-derived cells

The Department of Health and Human Services Food and Drug Administration (FDA) is seeking to procure human induced pluripotent stem cell-derived cells through a sole source solicitation. Specifically, the FDA aims to obtain differentiated human stem cell-derived cells including cardiomyocytes, neurons, astrocytes, and hepatocytes to support its microphysiological systems (MPS) research program. The solicitation, identified as FDA-Sole Source-126983, is focused on research and development in the physical, engineering, and life sciences under NAICS Code 541714. Potential vendors must submit questions by 10AM EST on April 21, 2025, with final responses due by 10AM EST on May 02, 2025. The FDA is justifying the sole source award under FAR 6.302-1, indicating a preference for continuity with an established contractor.

The solicitation is designated as an 8(a) Sole Source contract, with Fujifilm Cellular Dynamics identified as the intended sole source contractor based on their established work over the past five years. The procurement is specifically targeting a contractor with proven capabilities in producing high-quality, differentiated stem cell-derived cells for research purposes. While specific award values are not explicitly stated, the contract appears to be an Indefinite Delivery/Indefinite Quantity (IDIQ) arrangement that will support multiple FDA research projects. Interested parties may submit a capability statement within 15 days of publication, though the notice emphasizes this is not a competitive quote request. The place of performance is implied to be within the FDA's research facilities, likely associated with the Center for Drug Evaluation and Research, supporting advanced scientific research into cellular technologies and drug development methodologies.